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A practical and sensitive method of quantitating
lymphangiogenesis in vivo
Mousumi Majumder1, Xiping Xin1 and Peeyush K Lala1,2,3

To address the inadequacy of current assays, we developed a directed in vivo lymphangiogenesis assay (DIVLA) by
modifying an established directed in vivo angiogenesis assay. Silicon tubes (angioreactors) were implanted in the dorsal
flanks of nude mice. Tubes contained either growth factor-reduced basement membrane extract (BME)-alone (negative
control) or BME-containing vascular endothelial growth factor (VEGF)-D (positive control for lymphangiogenesis) or FGF2/VEGF-A (positive control for angiogenesis) or a high VEGF-D-expressing breast cancer cell line MDA-MD-468LN (468-LN),
or VEGF-D-silenced 468LN. Lymphangiogenesis was detected superficially with Evans Blue dye tracing and measured in
the cellular contents of angioreactors by multiple approaches: lymphatic vessel endothelial hyaluronan receptor-1 (Lyve1)
protein (immunofluorescence) and mRNA (qPCR) expression and a visual scoring of lymphatic vs blood capillaries with
dual Lyve1 (or PROX-11 or Podoplanin)/Cd31 immunostaining in cryosections. Lymphangiogenesis was absent with BME,
high with VEGF-D or VEGF-D-producing 468LN cells and low with VEGF-D-silenced 468LN. Angiogenesis was absent with
BME, high with FGF-2/VEGF-A, moderate with 468LN or VEGF-D and low with VEGF-D-silenced 468LN. The method was
reproduced in a syngeneic murine C3L5 tumor model in C3H/HeJ mice with dual Lyve1/Cd31 immunostaining. Thus,
DIVLA presents a practical and sensitive assay of lymphangiogenesis, validated with multiple approaches and markers. It
is highly suited to identifying pro- and anti-lymphangiogenic agents, as well as shared or distinct mechanisms regulating
lymphangiogenesis vs angiogenesis, and is widely applicable to research in vascular/tumor biology.
Laboratory Investigation (2013) 93, 779–791; doi:10.1038/labinvest.2013.72; published online 27 May 2013

KEYWORDS: angioreactor; breast cancer; DIVLA; lymphangiogenesis; lymphatic metastasis

The study of lymphangiogenesis is an emerging field of research for defining the fundamental mechanisms of lymphatic
vessel growth and function under physiological and pathological conditions.1,2 This knowledge serves as the key to
therapeutic applications for both blocking and promoting
lymphangiogenesis. For example, an association between
intra- or peritumoral lymphangiogenesis with lymphatic
metastasis in many cancers3–5 suggests that newly formed
lymphatics serve as conduits for lymphatic invasion and
spread of cancer cells to lymph nodes. This is often the first
route of spread in many cancers that can subsequently
metastasize from the lymph nodes to other organs via the
blood stream. Thus, inhibition of lymphangiogenesis might
offer a new opportunity for intervention of metastasis.
Conversely, dysfunction of lymphatic vessels often leads to
primary and secondary lymphedema, which markedly impairs

the function of affected tissues or organs. Thus, delivery of
lymphangiogenic factors to these affected tissues or organs
might restore their functions by establishing functional
lymphatic networks.6 Research on lymphangiogenesis was
long limited by the lack of lymphatic-specific markers and
suitable experimental models. Anatomical identification of
the lymphatic system in small animals, generation of
transgenic mouse models and recent in vitro models of
culturing lymphatic endothelial cells (LECs) or lymphatic
vessel explants have all paved the way for a new era in this
research.7
Numerous in vitro systems have been developed to study
lymphangiogenesis utilizing LECs from various sources:7 (a)
lymphatic-rich lesions induced by injecting Freund’s adjuvant,
(b) explants of thoracic duct fragments, (c) LEC differentiation
induced in embryoid bodies and (d) immune-purified primary
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or immortalized human dermal LEC. LECs, when placed on
collagen gel or matrigel, align themselves to form tube-like
structures under appropriate stimuli.8 However, most of these
systems suffer from limitations including the short life or
limited number of primary cells, or possible non-physiological
nature of immortalized cells. In a more physiological,
organotypic model of thoracic duct rings explanted in
collagen gels allows lymphatic capillary-like sprouting under
stimulated conditions, which can be quantified by computerassisted imaging.7 In our experience, this assay is time- and
labor-intensive, requiring the death of many young mice of
identical strain and sex for harvesting thoracic ducts, and low
oxygen culture conditions that require standardization. None of
these in vitro assays can adequately address the issues of realtime quantification of the growth of lymphatic vessels in vivo,
with lumens and lymphatic stability, which are essential for the
maintenance of lymphatic functions. For these reasons, a
reliable, quick and powerful in vivo lymphangiogenesis assay is
urgently needed.
Unlike blood vessels, lymphatics are not perfused with red
blood cells and thus remain poorly visible in a given tissue.
Their macroscopic detection is facilitated by the uptake of dyes
such as Evans Blue or India ink from the extravascular space.9
At the microscopic level, immunohistochemical staining for
specific markers such as lymphatic vessel endothelial
hyaluronan receptor-1 (Lyve1), vascular endothelial growth
factor receptor 3 (VEGFR3) or Podoplanin (Pdpn) or PROX-1
(Prox1) provides an opportunity for visualization of lymphatic
microvessels.10–13 Examples of in vivo models manipulating
lymphangiogenesis include (a) induction of tumor-associated
lymphangiogenesis by VEGF-C or -D overexpression in tumor
cells8,14,15 or in transgenic mice,16,17 (b) lymphatic hyperplasia
induced by intraperitoneal injection of incomplete Freund’s
adjuvant,18 (c) implantation of growth factor-containing
pellets into corneal micropockets19,20 and (d) the use of
avian chorioallantoic membrane (CAM) to stimulate
lymphangiogenesis.21 Each assay has its own advantages and
limitations depending on the objectives. However, some of
them may include masking effects, for example, of native
embryonic lymphangiogenesis in the CAM assay, or of
inflammatory mediators produced by injection of
incomplete Freund’s adjuvant. Furthermore, many of these
in vivo assays are time consuming and often qualitative, or at
best, semiquantitative. To overcome these limitations, we have
developed a quick, practical and quantitative in vivo assay for
measuring lymphangiogenesis by implanting angioreactors in
the mouse dorsal flanks. This method, an adaptation of the
directed in vivo angiogenesis assay (DIVAA),22–24 is highly
reproducible, providing an opportunity to quantify accurately
lymphangiogenesis as early as 10 days. It is applicable to many
objectives including quick preclinical screening of drugs
in vivo. We name this method as ‘directed in vivo
lymphangiogenesis assay’ (DIVLA). To illustrate its power,
here we used a human breast cancer cell line MDA-MB468LN, expressing high levels of VEGF-D but little VEGF-C or
780

VEGF-A, and its VEGF-D-silenced derivative, to quantitate
VEGF-D-dependent, tumor-associated lymphangiogenesis in
nude mice. To reproduce DIVLA in immunocompetent mice,
we used a syngeneic murine breast cancer cell line C3L5 that
produced VEGF-C and -D in a cyclo-oxygenase (COX)-2dependent manner.25
MATERIALS AND METHODS
Human Cell lines
Human breast cancer cell line MDA-MB-468LN (henceforth
called 468LN) is a lymphatic metastatic variant of the
MDA-MB-468 line.26 Cells were used from the original stock
shortly after their generation. We established stable VEGF-D
knocked down 468LN cells using shRNA plasmids.8
Both 468LN- and VEGF-D-silenced 468LN cells (named
DVEGF-D/468LNs) were grown as monolayers in a-MEM
supplemented with 10% FBS, 50 U/ml penicillin and
50 mg/ml streptomycin (all materials from GIBCO/
Invitrogen, ON, Canada).
Murine Cell Line
C3L5 is a COX-2-expressing, PGE2-, VEGF-C- and VEGF-Dsecreting murine breast cancer cell line produced in our
laboratory, the VEGF-C- and -D-secreting ability primarily
attributed to COX-2 activity.25,27 Cells were maintained in
high glucose DMEM (GIBCO, Grand Island, NY, USA)
supplemented with 5% fetal bovine serum, 100 U/ml
penicillin G and 100 mg/ml streptomycin in a humidified
incubator with 5% CO2 at 37 1C.
Mice
Four- to five-week-old athymic nude female mice (Hsd.
Athymic Nude-Foxn1nu/Foxn1 þ , Harlan, IN, USA) and C3H/
HeJ mice (obtained from the Jackson Laboratory) were
allowed to acclimatize for 2 weeks, maintained, respectively,
in barrier or traditional facilities, on standard mouse chow
and tap water on a 12 h light/dark cycle and treated in
accordance with the guidelines set by the Canadian Council
on Animal Care.
Directed In Vivo Lymphangiogenesis
We significantly modified a directed in vivo angiogenesis
assay23 to measure lymphangiogenesis in addition to
angiogenesis. Briefly, sterile angioreactors (Cat. No. 3450048-01; Trevigen, Gaithersburg, MD, USA) were prechilled at
4 1C and filled with 20 ml of either growth factor-reduced
basement membrane extract (BME) (Cat. No. 3450-048-02;
Trevigen) alone or 40  103 468LN or DVEGF-D/468LN cells
in 2 ml a-MEM with 18 ml BME, or 18 ml BME with
recombinant VEGF-D (20 ng in 2 ml) (622-VD-005; R&D
Systems, CA, USA) or FGF-2 (225 ng)/VEGF-A (75 ng) (Cat.
No. 3450-048-B10; Trevigen), the latter two used as respective
positive controls for lymphangiogenesis and angiogenesis.
Angioreactors were incubated at 37 1C for 1 h to allow BME
gel formation, before subcutaneous implantation into the
Laboratory Investigation | Volume 93 July 2013 | www.laboratoryinvestigation.org
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dorsal flank of 8-week-old female nude mice. Mice were
anesthetized with isoflurane (Baxter, Mississauga, ON,
Canada) and angioreactors (4 with identical conditions per
mouse; 4–8 mice per condition; Figure 1) implanted in the
dorsal flank. After the defined experimental period of 10
days, mice were anesthetized to expose the angioreactors. The
skin surrounding the angioreactors was cut and opened with
fine dissection scissors (Figure 1). Evans Blue was injected
near the angioreactor to capture images of dye-stained
lymphatics immediately and at short intervals up to 25 min
with both a digital camera (Nikon, D-90) and a dissection
microscope. Subsequently, mice were euthanized humanely
to retrieve the angioreactors used for three different purposes
(Figure 1). One of them was carefully removed without
severing the ingrowing vessels and excising the rest of the

tissues with fine scissors and flash-frozen immediately with
dry ice for making cryosections. The other three were removed from the surrounding tissues by excising along the
margins to sever any vessel that may be growing into them,
and lifting them with dissection forceps. They were used to
collect cellular contents and conduct lymphatic ingrowth
assay and RNA extraction for real-time gene expression as
detailed below.
Evans Blue Dye Tracing
Approximately 2 ml of 4% Evans Blue dye (Sigma-Aldrich,
San Francisco, CA, USA) diluted with PBS was injected
subcutaneously in nude mice with a 30 G needle at about
2 cm distance from the angioreactor implants, allowing a
visual tracing of lymphatics growing into the angioreactors.

Figure 1 Workflow of directed in vivo lymphangiogenesis assay (DIVLA). Four angioreactors were implanted in one mouse. (a) After 10 days of
implantation, mouse dorsal flank exposed to visualize angioreactors (black dotted line) and the surrounding vasculature. (b) Digital camera image (DCI)
immediately following Evans Blue (EB) dye injection (white dotted line) at two to three points near the angioreactors. (c) DCI of EB drainage by
lymphatics observed at 5 min intervals after injection; (d) image captured with dissection microscope at 5-min intervals up to 25 min after injection.
(e) One angioreactor collected with intact surrounding tissue without disrupting the vascular ingrowth and embedded with OCT compound followed
by flash freezing. The remaining three angioreactors were taken out to retrieve cellular contents. (f) Of the latter, one tube was used for
immunofluorescence assay and (g) two were used for RNA extraction. DAPI, 40 ,6-diamidino-2-phenylindole.
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Images were captured at 5–25 min after injection under a
dissection microscope (Nikon SMZ1500).
Retrieval of Cellular Contents from Angioreactors
Under stimulated conditions, lymphatics as well as blood
vessels grew into the angioreactors, invading the BME. To
quantitate lymphatic vessel ingrowth, angioreactors were removed from the surrounding tissues. The cellular contents
were retrieved by cutting one end and squeezing the tube.
The tubes were rinsed two times with CellSperse solution
(Cat. No. 3450-048-05; Trivigen) to retrieve remaining tissue,
which was incubated in 200 ml of the solution for 1 h at 37 1C
to digest the BME. The incubation mix was then washed
three times with wash buffer (Cat. No. 3450-048-03; Trivigen) and centrifuged (1500 r.p.m. for 5 min) to get a BMEfree cell pellet. The pellet was resuspended in 500 ml a-MEM
supplemented with 10% FBS and incubated at 37 1C for 1 h
to allow cell surface recovery.
Quantitation of Lymphatic Ingrowth
Each cell pellet was treated with 400 ml DIVAA 1  Dilution
Buffer (Cat. no. 3450-048-07; Trivigen) and rabbit antimouse Lyve1 antibody (Cat. No. 11-034; AngioBio, Del Mar,
CA, USA; diluted 1:500) and incubated at 4 1C overnight.
Then, cells were washed three times for 5 min with 1  TBST
(1  PBS/0.3% Triton X-100) and treated with Alexa Fluor
594 (Invitrogen) anti-rabbit secondary antibody (1:5000 dilution) and incubated for another 1 h. After three further
washes, cells were resuspended in 200 ml wash buffer and
fluorescence was measured in a 96-well plate using a
FLUOstar Omega (Bmg Labtech, Fisher Scientific, CA, USA)
spectrofluorimeter (excitation 584 nm, emission 620 nm, gain
1500–3000). The mean fluorescence (±s.e.) for 16 replicate
assays was determined.
Expression of Lymphatic and Vascular Endothelial Cell
Marker mRNAs
In our pilot study with four mice, we observed that the yield
of mRNA extracted from cell pellets recovered from a single
angioreactor was inadequate. Hence in our definitive experiments, we pooled the contents of two angioreactors from
the same mouse (identical condition) (Figure 1). Total RNA
was extracted from cell pellets using Qiagen RNeasy (Qiagen,
Toronto, ON, Canada). Synthesis of cDNA and quantitative
(q) RT-PCR was performed for murine Lyve1
(Mm00475056_m1), Cd31 (Mm01242584_m1) and b-actin
(4352933E) genes with TaqMan Gene Expression Assays
(Applied Biosystems).
Direct Visualization and Measurements of
Lymphangiogenesis and Angiogenesis
The surgically excised tissue including the angioreactor was
placed on a disposable vinyl specimen mold, which was then
secured and flash frozen on dry ice with OCT compound
(Tissue-Tek*, Sakura Finetek USA, Torrance, CA, USA), and
782

the samples were stored at  20 1C until further processing as
follows. Angioreactors were cut longitudinally on a cryostat
(Leica CM3050 S) into two halves to place the contents on
specimen molds and covered with HistoGel (Thermo Fisher
Scientific, Burlington, ON, Canada). Then, the molds were
mounted with OCT and frozen again on dry ice. Subsequently, the molds were placed on a cryostat, sections cut at
5–6 mm, and the serial sections picked up on a colorfrost plus
slide (Fisher Scientific). Adjacent serial sections were separately stained with hematoxylin/eosin to identify cell morphology, and dual immunostained to visualize lymphatics
(Lyve1 or Prox1 or Pdpn staining) and blood vessels (Cd31
staining). To evaluate possible macrophage staining with
Lyve1 reported in some studies,28 sections were also doublestained for Lyve1 and F4/80. All the secondary antibodies and
species-specific sera were from Life Technologies (Burlington,
ON, Canada). Frozen sections were fixed in ice-cold acetone
for 5 min at 4 1C; all of the subsequent steps were performed
at room temperature. Slides were rehydrated for 10 min in
PBS, followed by incubation for 20 min at room temperature
in blocking buffer (5% normal goat serum in PBS with 0.3%
Triton X-100) to block nonspecific antibody binding.
Sections were then treated for 1 h with primary rat
monoclonal Cd31 antibody, (MEC 13.3; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) 1:200, in dilution
buffer PBST (1  PBS/2% BSA/0.3% Triton X-100).
Following washing steps with blocking buffer, sections were
treated with rabbit anti-mouse Lyve1 or Prox1 (Acris
Antibodies, San Diego, CA, USA), or Pdpn (Bioss,
Wouburn, MA, USA) antibodies, 1:200, in dilution buffer
in the dark for 2 h at room temperature. For macrophage
staining, slides were incubated with Lyve1 antibody, followed
by rat anti-mouse F4/80 antibody (Abcam, Toronto, ON,
Canada), 1:200, in the dark for 2 h at room temperature.
Following three washes with 1  PBST, either Alexa Fluor 647
donkey anti-rabbit or goat anti-rabbit Alexa Fluor 594
secondary antibodies, 1:2000, were applied to detect Lyve1,
Prox1 and F4/80 in far red or red channel, respectively. On
the other hand, for Cd31, sections were stained with either
Alexa Fluor 594 Goat Anti-rat IgG (H þ L) to detect in red
channel or with goat anti-rat Alexa Fluor 488 to detect in
green channel. In the case of Pdpn, Alexa Fluor 594 donkey
anti-rabbit and either Alexa Fluor 647 goat anti-rat or goat
anti-rat Alexa Fluor 488 secondary antibodies were added in
1:2000 dilution to detect Pdpn in red and Cd31 in far red or
green channel. Sections were incubated for 30 min at room
temperature, washed with PBS, dried and mounted with
Vectashield solution (Vector Laboratories, Burlington, ON,
Canada). They were scanned at low magnification (  250)
under a BX51 microscope (Olympus) to identify the most
vascular areas within the angioreactor. Exclusion of the
primary antibody step was used as the negative control in
each case to ascertain staining specificity. Representative
images were taken with confocal microscope (Zeiss LSM510
META). Micro (blood) vessel density (MVD) and lymphatic
Laboratory Investigation | Volume 93 July 2013 | www.laboratoryinvestigation.org
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vessel density (LVD) were assessed in dual-immunostained
sections as reported.25,29 Three hotspots per section (areas of
highest vascular density in the descending order, 24 per group)
were identified and examined at  400 magnification.
The incidence of marker-positive vascular-like structures
(irrespective of complete or incomplete lumen, depending on
the plane of section) per unit area was scored after setting the
threshold for background, using the Image-J software (NIH,
Bethesda, MD, USA).25 The mean values for MVD vs LVD
were computed as the staining indices for Cd31 (red) vs Lyve1
or Prox1 (far red, depicted as sky blue), or Cd31 (far red,
depicted as sky blue) vs Pdpn (red). We had earlier shown that
the ‘hotspot’ method provides results that are relatively very
similar to those provided by the vascular density scores
obtained by scanning the total area of the section.29
Following exactly the same procedure, C3H/HeJ mice received four angioreactors each containing BME and 40  103
C3L5 cells in shaven dorsal flank. Mice (two per treatment
group) were treated for 9 days before being killed. Treatment
regimens included Celecoxib (125 mg/kg by oral gavage, two
times daily), or 0.5% methylcellulose (Sigma), which served
as the vehicle control. After 9 days, angioreactors retrieved

from mice were subjected to dual immunofluorescent labeling for murine Lyve1 (green) and Cd31 (red) in frozen sections. The mean values for MVD and LVD were computed as
the staining indices as described above.
Statistics
Data were analyzed using the Sigma Stat (version 3.5; Systat,
San Jose, CA, USA). All parametric data were analyzed using
a one-way ANOVA and a Tukey–Kramer comparisons post
hoc test. A Student’s t-test was used to compare two data sets.
All statistical tests were two-sided, and data were considered
statistically significant at Po0.05.
RESULTS
In this illustrative study, we used MDA-MD-468LN and
DVEGF-D/468LN cells to examine the role of VEGF-D
expression by tumor cells on tumor-induced lymphangiogenesis in vivo. VEGF-D secretion (24 h, in serum-free medium)
by these cells were, respectively, 229.50 pg/ml for 468LN and
48.33 pg/ml for DVEGF-D/468LN, measured by ELISA.8
In the illustrative study, tubes containing BME alone
provided the negative control; those with recombinant

Figure 2 Evans Blue dye tracing. Dye injection site is outlined by yellow. Arrowhead showing density of blue lymphatic network was high and directed
towards the open ends of angioreactors (black lining) containing 468LN cells (upper panel). In contrast, very poor dye infiltration indicative of
lymphatic network formation was detected near the tubes (black lining) containing DVEGF-D/468LN cells (lower panel, arrowhead). Images captured
with a dissection microscope are shown at different magnifications (see inset) at different time intervals. VEGF, vascular endothelial growth factor.
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VEGF-D and with FGF-2/VEGF served as respective
positive controls for lymphangiogenesis and angiogenesis.
Using these five types of implants, we quantified both

lymphangiogenesis and angiogenesis with indirect and direct
measurements in nude mice as outlined in Figure 1 and
detailed in methodology.

Figure 3 Lymphatic ingrowth assay and mRNA expression. (a) To determine the temporal kinetics of lymphatic network formation and stability, in a
pilot study, four mice (for eachtime point, were killed on days 6, 9 and 12. Levels of lymphatic vessel endothelial hyaluronan receptor-1 (Lyve1) and
Cd31 mRNA expression in cellular contents of angioreactor were measured and data presented relative to basement membrane extract (BME) alone.
(b) Red blood cells were visibly higher in tubes containing 468LN cells than those with DVEGF-D/468LN cells. FGF-2/VEGF served as positive control for
angiogenesis, rVEGF-D as positive control for lymphangiogenesis and BME as background control for both. (c) Cells isolated from tubes and labeled
with mouse Lyve1 antibody to measure the relative incidence of lymphatic endothelial cells. Lyve1 expression is presented as raw fluorescence scores
without background correction for BME alone. Expression of Lyve1 was significantly lower in tubes containing DVEGF-D/468LN cells as compared with
468LN, rVEGF-D and FGF-2/VEGF tubes. (d) Lyve1 and Cd31 mRNA expression was measured with cells collected from angioreactor and data presented
relative to BME alone. Lyve1 expression was the highest with rVEGF-D, and Cd31 expression the highest with FGF-2/VEGF. VEGF-D knockdown
markedly reduced the expression of both markers in DVEGF-D/468LN cells compared with 468LN cells. Bars in (b) and (c) represent mean (n ¼ 16)±s.e.
*Po0.05; **Po0.005. FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor.

Figure 4 Direct measurement of lymphangiogenesis and angiogenesis with rVEGF-D in nude mice. (a) Representative sections of angioreactors
showing cellular morphology in hematoxylin and eosin staining. Vascular-like networks can be seen in tubes with rVEGF-D (arrowheads). Images taken
with  10 objectives scale bar represents 200 mm. (b) Immunofluorescent labeling for murine lymphatic vessel endothelial hyaluronan receptor-1
(Lyve1) or PROX-1 (Prox1) or Pdpn and Cd31 markers in serial frozen sections of angioreactors, containing rVEGF-D, served as positive control for
lymphangiogenesis. In merged pictures, lymphatics are shown with arrowheads in white and blood vessels in yellow. A few lumens (white arrows) were
observed. While significant angiogenesis as well as lymphangiogenesis was evident from all the markers, no significant overlap was noted between
Lyve1 and Cd31 staining of endothelial cells. BME, basement membrane extract; DAPI, 40 ,6-diamidino-2-phenylindole; VEGF, vascular endothelial growth
factor.
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Indirect Measurements
VEGF-D knockdown in tumor cells reduces the density of
visible lymphatic network on the surface and ingrowth of
lymphatics into the angioreactors
Blood vessels including blood capillaries are visibly red because of red cell content. Lymphatic networks are traceable
with Evans Blue dye. An abundance of dye-stained lymphatic
capillary network was visible around 468LN angioreactor
implants (arrowhead) at 10–25 min after injection (Figure 2,
upper panel). In contrast, in mice implanted with angioreactors containing DVEGF-D/468LN cells, Evans Bluemarked large lymphatics were visible, but lymphatic capillary
network around angioreactors were not visible even at 25 min
(Figure 2, lower panel, arrowhead).
To determine initiation of lymphangiogenesis and its
temporal kinetics, we conducted a pilot study in a small
number of mice. BME and 468LN served as respective
negative and positive controls. One mouse per group was
killed at each time points on days 6, 9 and 12. Levels of
angiogenesis and lymphangiogenesis were measured by
quantifying Cd31 and Lyve1 mRNA (Figure 3a). Significant
lymphangiogenesis was detected as early as day 6, increasing
to a plateau between days 9 and 12. Thus in the definitive
experiments, we killed the mice on day 10.
Red blood cell-containing vasculature within the angioreactors was evident once tubes were exposed. Tubes
containing 468LN cells or rVEGF-D alone showed significantly
detectable red blood cell content, the highest content observed
in the tubes containing FGF-2/VEGF, serving as positive
control for angiogenesis. VEGF-D knockdown in 468 LN cells
resulted in a marked reduction in red blood cell content
(Figure 3b). Results from immunofluorescence assay for
lymphangiogenesis marker Lyve1 (uncorrected for the background provided by BME alone, used as negative control)
revealed that Lyve1-labeled murine LECs were recruited into
the angioreactors during lymphangiogenesis. Lyve1 signal was
significantly greater in cells collected from 468LN angioreactor
than DVEGF-D/468LN angioreactor (Figure 3c). As expected,
the signal was the highest in BME containing rVEGF-D used as
positive control for lymphangiogenesis.
VEGF-D knockdown reduces the expression of both murine
Lyve1 and Cd31 mRNA
To quantify at mRNA levels indicative of the relative abundance of mouse lymphatics and blood vessels within the
angioreactors, we took advantage of the mouse lymphatic
endothelial marker Lyve1 and angiogenesis marker Cd31. As
expected, implants with FGF-2/VEGF exhibited high Cd31
but very low Lyve1 mRNA, and those with rVEGF-D showed
very high Lyve1 but low Cd31 mRNA, whereas implants
with BME alone expressed very little of either mRNA.
Finally, there was a significant reduction in both Lyve1 and
Cd31 mRNA expression in cells collected from DVEGF-D/
468LN-containing angioreactors, as compared with 468LN
angioreactors (Figure 3d).
786

Direct Measurements
VEGF-D knockdown in 468LN cells reduces both
lymphangiogenesis and angiogenesis within the angioreactors
Hematoxylin and eosin-stained sections of angioreactor
contents (Figure 4a) revealed very few cells in BME alone,
whereas an abundance of cells inclusive of vascular-like
networks was noted in angioreactors containing r-VEGF-D,
468LN or DVEGF-D/468LN cells. Dense vascular-like networks were noted in VEGF-D-containing angioreactors. All
three antibodies (Lyve1 or Prox1 or Pdpn) showed specific
staining of lymphatic network in sections of angioreactors
containing r-VEGF-D, used as positive control for lymphangiogenesis. Blood vessels were stained with Cd31 in the
same sections (Figure 4b). We directly measured the levels of
lymphangiogenesis and angiogenesis in serial cryosections of
angioreactors with dual immunolabeling for Lyve1 or Prox1
(sky blue) and Cd31 (red) or Pdpn (red) and Cd31 (sky
blue), respectively, using the ‘hotspots’, as reported. The unit
scores are the means of three hot spots (as detailed in the
Materials and Methods) under each treatment condition,
representing the incidence of marker-positive vascular-like
structures (with or without complete lumens) per unit area.
High levels of tumor-associated lymphangiogenesis as well
as angiogenesis occurred in 468LN-containing implants.
Unsurprisingly, many lymphatic and blood vessels coexisted
in intimate contact. Incidences of both vascular structures
were significantly lower in DVEGF-D/468LN cell-containing
implants (images shown in Figure 5a; quantitation in
Figure 5b). No measurable angiogenesis or lymphangiogenesis was observed in BME-alone implants (data not
shown). Some EGFP-tagged 468LN and DVEGF-D/468LN
cells (green) were also noted in unlabeled angioreactor
sections (Figure 5a). To test whether macrophages stained for
Lyve1 as reported in some studies,28 some serial sections were
also double-stained for F4/80 (red) and Lyve1 (sky blue)
(Figure 6). The results showed little or no Lyve1 staining by
F4/80-positive cells.
Therapy with COX-2 inhibitor reduces both lymphangiogenesis
and angiogenesis within the angioreactor-containing C3L5 cells
In 9-day-old implants of C3L5-containing angioreactors in
C3H/HeJ mice, data revealed a very high incidence for both
Lyve1- and Cd31-stained vascular structures in vehicle-treated mice, which was significantly reduced in Celecoxib-treated mice (Supplementary Figure 1). These results are highly
consistent with our earlier report of inhibition of tumor
growth, tumor-associated lymphangiogenesis and angiogenesis and spontaneous metastasis to the lymph nodes and
the lungs in this tumor model following Celecoxib therapy.25
DISCUSSION
Here we describe a practical, sensitive and quantitative assay
for measuring lymphangiogenesis in vivo within a short time
frame of 9–10 days utilizing multiple approaches, including
direct immunohistochemical identification and scoring of
Laboratory Investigation | Volume 93 July 2013 | www.laboratoryinvestigation.org
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Figure 5 See next page for caption.
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Figure 5 Measurements of lymphangiogenesis and angiogenesis in
tubes containing 468LN and DVEGF-D/468LN cells. (a) Immunofluorescent
labeling for murine lymphatic vessel endothelial hyaluronan receptor-1
(Lyve1) or PROX-1 (Prox1) (sky blue) and Cd31 (red) or Pdpn (red) and
Cd31 (sky blue) markers in serial frozen sections of angioreactors
revealed significantly higher labeling for all markers in 468LN-containing
sections (white arrowheads showing staining of either Lyve1 or Prox1 or
Pdpn and yellow arrowheads showing Cd31 staining in merged pictures)
compared with DVEGF-D/468LN sections. Nuclei were stained with DAPI,
40 ,6-diamidino-2-phenylindole (DAPI) (royal blue). Some enhanced green
fluorescent protein (EGFP)-tagged 468LN and DVEGF-D/468LN cells
(green) were also visible. A few of the vessels show evident lumens
(white arrows). Magnifications are shown as insets in the merged picture,
scale bars representing 50 mm. (b) Quantification of ‘hotspot’ scores for
Cd31 and Lyve1 or Prox1 or Pdpn made under  40 objective (n ¼ 8,
using the mean of three hot spots from each of the eight angioreactors
per group)±s.e., *P ¼ 0.0001. VEGF, vascular endothelial growth factor.
The color reproduction of this figure is available on the Laboratory
Investigation journal online.

lymphatic capillaries. In this assay, most of our experiments
were conducted in nude mice using the MDA-MB-468LN cell
line, a lymph node-metastasizing variant of the MDA-MB468 human breast adenocarcinoma cell line. The assay was
further validated with a single experiment using a highly
metastatic murine C3L5 breast cancer cell line in immunocompetent mice. In an earlier study, utilizing numerous other
788

in vitro assays and tumor xenotransplants in nude mice, we
have defined the multiplicity of mechanisms underlying the
capacity of the 468LN cells in promoting lymphangiogenesis,
lymphovascular invasion and lymphatic metastasis.8 We
showed that they resulted from the dual overexpression of
a9b1-integrin and its ligand VEGF-D by 468LN cells. The
limitation of the above-mentioned tumor model is that it is
time consuming for the xenograft to produce tumors of
appreciable sizes to measure intratumoral lymphangiogenesis. In a syngeneic mouse model of breast cancer
expressing both VEGF-C and VEGF-D, in which tumors
grew rapidly and quickly metastasized to lymph nodes, the
same results were achievable as early as 12 days.25 We show
here that the current assay is equally applicable to this tumor
model in immunocompetent mice tested at 9 days. However,
xenografted human tumor models being best suited to
preclinical testing of drugs, the present assay is ideally suited
for such preclinical validation.
DIVAA is an excellent well-studied model to measure
angiogenic factor-induced angiogenesis or its inhibition with
angiostatic agents after implanting angioreactors in the
mouse dorsal flank.23 This is an improvement on the matrigel
plug assay as reported by us for tumor-associated
angiogenesis,29 by containing the BME (or matrigel) in a
silicon cylinder to direct the ingrowth of newly formed
capillaries into the open end of the cylinder. DIVAA has been
effectively applied to studies of both proangiogenic30 and
antiangiogenic24 functions of various agents. We modified
and applied this method to quantify lymphangiogenesis
and coined the term DIVLA or directed in vivo
lymphangiogenesis assay. This method is quick, highly
quantitative and can be applied to a variety of studies,
including preclinical testing of agents for their ability to
block or promote lymphangiogenesis in vivo. As many
compounds or tumor cells may have a dual effect on
angiogenesis and lymphangiogenesis, as illustrated in this
study in the case of VEGF-D, or 468LN or C3L5 cells, its
capability for a simultaneous measurement of angiogenesis is
an additional advantage. VEGF-D, although well known for
its capacity to promote lymphangiogenesis by virtue of
binding to VEGF-R3 expressed by lymphatic endothelial
precursors, can also bind to VEGF-R2 expressed by vascular
endothelial precursors to promote angiogenesis, explaining
the dual effect in this study using either 468LN cells
(expressing high levels of VEGF-D, but not VEGF-C or
VEGF-A) or recombinant VEGF-D in the BME of implanted
angioreactors. Knocking down VEGF-D in 468LN cells
significantly abrogated both events. This was also the case
with Celecoxib therapy in the case of C3L5 cells producing
both VEGF-C and VEGF-D, resulting from COX-2
expression. As clearly demonstrated in our results, implants
containing growth factor-reduced BME alone showed no sign
of angiogenesis or lymphangiogenesis in any of the indirect
or direct measurements in our assay, eliminating any role of
the matrix in the implanted angioreactors.
Laboratory Investigation | Volume 93 July 2013 | www.laboratoryinvestigation.org
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Figure 6 Dual immunostaining for lymphatic vessel endothelial hyaluronan receptor-1 (Lyve1) and F4/80. Immunofluorescent labeling for Lyve1 (sky
blue) and F4/80 (red, macrophage marker) in frozen sections of angioreactors. Merged pictures (Lyve1, white arrowhead; F4/80, yellow arrowhead)
revealed very little or no overlap between the two markers. Nuclei were stained with 40 ,6-diamidino-2-phenylindole (DAPI) (royal blue). Some enhanced
green fluorescent protein (EGFP)-tagged 468LN and DVEGF-D/468LN cells (green) were also visible. Magnifications are shown as insets in the pictures,
scale bars representing 50 mm. DAPI, 40 ,6-diamidino-2-phenylindole.

A simpler matrigel plug assay without the inclusion of
angioreactors, in our hands, does not provide as robust
results because of the undirected nature of the lymphatic
vessel ingrowth, as well as a poorer containment of tumor
cells within the implant. Inclusion of tumor cells in the BME
within the angioreactor makes its application highly suited
for studies of tumor biology and translational cancer
research, as has been exploited with the DIVAA model.22,23
The role of tumor-associated lymphangiogenesis in
lymphatic metastasis has been suggested by an association
between tumoral expression of the lymphangiogenic factors
VEGF-C or -D and lymphatic metastasis in many epithelial
cancers including cancers of the prostate,31 stomach32 and
the colon.33 This has been validated by a direct association
between intra- or peritumoral lymphangiogenesis with
lymphatic invasion and metastasis in cancers of the
breast,4,5 pharynx and larynx.3 Thus, this assay should
have a broad application for preclinical testing of agents
with potentials for prevention or intervention of lymphatic
metastasis.
Multiple quantitative measurements and markers
described in this assay make our model more robust and
sensitive compared with the single measurement used for
angiogenesis in the original DIVAA assay.23 We used a variety
of approaches such as quantification of the Lyve1 protein by
immunofluorescence, Lyve1 mRNA by qPCR from the
extracted tissues and direct immunolabeling of frozen
www.laboratoryinvestigation.org | Laboratory Investigation | Volume 93 July 2013

sections for multiple markers (Lyve1, Prox1 and Pdpn), all
of which gave the same answer, eliminating the limitations of
a single approach or a single marker. We found no evidence
of Lyve1-stained endothelial linings also staining for Cd31 in
our earlier study25 or this study. To exclude the possibility of
Lyve1 staining by macrophages reported in some studies28
leading to overestimate LVD, we double-stained tissue
sections with F4/80 and Lyve1 showing little or no overlap.
Furthermore, use of Prox113 and Pdpn12 as additional
markers provided very similar results.
This assay can be adapted to a direct testing of the drugs
included in the BME along with tumor cells (with drugs with
a long half-life), or of drugs given systemically to mice by the
enteral or parenteral routes and still get the results in 10 days.
There are many drugs that may have no direct effect on the
process of lymphangiogenesis, but can block tumor-induced
lymphangiogenesis by inhibiting pathways responsible for an
upregulation of lymphangiogenic factors such as VEGF-C or
VEGF-D produced by tumor cells. For example, expression of
COX-2 was shown to upregulate VEGF-C or -D in breast
cancer25,34 and lung cancer.35 In the case of breast cancer, this
was primarily due to an activation of prostaglandin receptor
EP4, so that both COX-2 inhibitor Celecoxib and the EP4
antagonist ONO-AE3-208 given orally were equally effective
in blocking tumor-associated lymphangiogenesis and
lymphatic metastasis in a COX-2-expressing mouse breast
cancer model.25 In this study, using DIVLA we have
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reproduced the effects of Celecoxib therapy in the same
tumor noted earlier with the matrigel plug assay.25
In conclusion, the DIVLA is an innovated version of the
DIVAA method for quick and efficient measurements of
lymphangiogenesis in combination with angiogenesis. It is
highly practicable in laboratories housing nude mice, with
training for implanting angioreactors. This implantation is
relatively easier in young (6–8 weeks old) nude mice than in
immunocompetent mice of similar age, which have a thicker
and hairy skin requiring shaving or depilation. The method
allows identification of new candidates that regulate
lymphatic vasculature, a screening for pro- and antilymphangiogenic agents, and exploring specific mechanisms
that underlie or differentially regulate the processes of
lymphangiogenesis and angiogenesis. We believe that it
presents advancement in vascular biology with the potential
of identifying common as well a distinct progenitors and
pathways for angiogenesis and lymphangiogenesis. In particular, it offers prospects for the design of strategies and drugs
to manipulate the lymphatic system, and thereby intervene
the processes of cancer metastasis and lymphedema.
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